Safety and efficacy of tetrastarches in surgery and trauma: a systematic review and meta-analysis of randomised controlled trials. (October 2021)

• Record Type: Journal Article
• Authors: Chappell, Daniel; van der Linden, Philippe; Ripollés-Melchor, Javier; James, Michael F.M.
• Is Part Of: British journal of anaesthesia. Volume 127:Number 4(2021)
• Page Start: 556
• Page End: 568
• Publication Date: 2021-10
• Subjects: colloids -- HES -- hydroxyethyl starch -- perioperative -- renal failure -- trauma -- volume therapy; Anesthesiology -- Periodicals; Anesthesia -- Periodicals; 617.9605
• DOI: 10.1016/j.bja.2021.06.040
• Languages: English
• ISSNs: 0007-0912

Abstract

Abstract: Background: Hydroxyethyl starch (HES) 130 is a frequently used fluid to replace intravascular losses during surgery or trauma. In the past years, several trials performed in critically ill patients have raised questions regarding the safety of this product. Our aim in this meta-analysis was to evaluate the safety and efficacy of 6% HES during surgery and in trauma. Methods: This systematic review and meta-analysis was registered at PROSPERO (CRD42018100379). We included 85 fully published articles from 1980 to June 2018 according to the protocol and three additional recent articles up to June 2020 in English, French, German, and Spanish reporting on prospective, randomised, and controlled clinical trials applying volume therapy with HES 130/0.4 or HES 130/0.42, including combinations with crystalloids, to patients undergoing surgery. Comparators were albumin, gelatin, and crystalloids only. A meta-analysis could not be performed for the two trauma studies as there was only one study that reported data on endpoints of interest. Results: Surgical patients treated with HES had lower postoperative serum creatinine ( P <0.001) and showed no differences in renal dysfunction, renal failure, or renal replacement therapy. Although there was practically no further difference in the colloids albumin or gelatin, the use of HES improved haemodynamic stability, reduced need for vasopressors ( P <0.001), and decreased length of hospital stay ( P <0.001) compared with the use of crystalloids alone. Conclusions: HES was shown to be safe and efficacious in the perioperative setting. Results of the present meta-analysis suggest that when used with adequate indication, a combination of intravenous fluid therapy with crystalloids and volume replacement with HES as colloid has clinically beneficial effects over using crystalloids only.